<DOC>
	<DOCNO>NCT01040845</DOCNO>
	<brief_summary>This study evaluate effect , , twice daily dose colchicine 0.6 mg steady state steady state pharmacokinetic profile ethinyl estradiol norethindrone ( Ortho-Novum 1/35 ) . It also evaluate effect , , steady state ethinyl estradiol norethindrone colchicine steady state . Finally , study assess safety tolerability concurrent use colchicine estrogen/progesterone-containing oral contraceptive .</brief_summary>
	<brief_title>A Pharmacokinetic Study Colchicine With Oral Contraceptive</brief_title>
	<detailed_description>This study evaluate effect , , twice daily dose colchicine 0.6 mg steady state steady state pharmacokinetic profile ethinyl estradiol norethindrone ( Ortho-Novum 1/35 ) . It also evaluate effect , , steady state ethinyl estradiol norethindrone colchicine steady state . Finally , study assess safety tolerability concurrent use colchicine estrogen/progesterone-containing oral contraceptive . Following optional single cycle run-in period subject take oral contraceptive switch Ortho-Novum 1/35 , 30 healthy adult female volunteer child bear age ( 18-45 year old ) randomize double blind crossover fashion receive two ethinyl estradiol norethindrone dose regimen sequence . During two dose period , subject receive one ethinyl estradiol norethindrone tablet morning Days 1-7 cycle . On day 8-21 , subject receive twice daily dos either colchicine ( 0.6 mg capsule twice daily breakfast dinner ) placebo ( one capsule twice daily breakfast dinner ) , accord randomization schedule , along one ethinyl estradiol norethindrone tablet . Subjects receive alternate dose regimen Cycle 2 . Blood sample draw time sufficient determine steady state pharmacokinetics ethinyl estradiol norethindrone without steady state colchicine . In addition , cycle active colchicine give , effect steady state ethinyl estradiol norethindrone steady state colchicine evaluate . Subjects monitor adverse effect throughout study via query spontaneous reporting . Additionally baseline 12 lead EKG vital sign compare obtain time point throughout study period .</detailed_description>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Norinyl</mesh_term>
	<mesh_term>Norethindrone acetate , ethinyl estradiol , ferrous fumarate drug combination</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Healthy , nonsmoking female volunteer childbearing potential age 18 45 year weigh least 55 kg within 15 % ideal body weight take oral contraceptive advice personal health care provider willing switch OrthoNovum 1/35 Subjects either sexually inactive use double barrier method contraception 14 day first dose study drug throughout study Pregnant lactating Recent ( 2year ) history evidence alcoholism drug abuse Test positive screening human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HbsAg ) , hepatitis C antibody ( HCV ) History presence significant cardiovascular , pulmonary , hepatic , renal , hematological , gastrointestinal , endocrine , immunologic , dermatologic , neurological , psychiatric disease Hemoglobin &lt; 12 g/dL Use drug substance know inhibit induce cytochrome ( CYP ) P450 enzymes and/or Pgp within 30 day prior first dose OrthoNovumÂ® 1/35 expect require use</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>healthy</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>drug-interaction</keyword>
</DOC>